Estimated positivity cut-offs for one and two sample contexts which give an equivalent population test positivity rate, together with respective sensitivities for advanced neoplasia
| Population test-positivity rate | Cut-off achieving population test positivity rate equivalence (µg Hb/g faeces) | Sensitivity (%, for advanced neoplasia, 95% CI) for sample context at that cut-off (n=626) | ||
| 1-sample | 2-sample* | 1-sample | 2-sample* | |
| 2% | 49.8 | 94.2 | 14.9% (n=93) 12.0%–17.7% | 15.3% (n=96) 12.6%–18.4% |
| 3% | 32.4 | 56.2 | 22.8% (n=143) 19.3%–26.0% | 21.9% (n=137) 18.9%–25.5% |
| 4% | 22.4 | 40.2 | 31.5% (n=197) 28.0%–35.4% | 29.1% (n=182) 25.4%–32.6% |
| 5% | 17.0 | 30.6 | 36.3% (n=227) 32.3%–40.0% | 37.2% (n=233) 33.3%–41.0% |
| 6% | 13.8 | 24.6 | 39.1% (n=245) 35.1%–42.9% | 47.3% (n=296) 43.2%–51.1% |
| 7% | 11.6 | 20.0 | 41.4% (n=259) 37.3%–45.2% | 54.3% (n=340) 50.2%–58.1% |
| 8% | 9.8 | 16.6 | 44.4% (n=278) 40.3%–48.2% | 55.1% (n=345) 51.8%–58.9% |
| 9% | 8.4 | 14.4 | 45.8% (n=287) 41.7%–49.7% | 55.8% (n=349) 51.6%–59.5% |
| 10% | 7.4 | 12.8 | 46.8% (n=293) 42.7%–50.6% | 56.7% (n=355) 52.7%–60.6% |
*Maximum value of the two samples.